我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

健肝消脂方对非酒精性脂肪性肝病胰岛素抵抗、脂质沉积的影响 及相关mRNA差异表达初步分析*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2019年02期
页码:
1-10
栏目:
实验研究
出版日期:
2019-11-15

文章信息/Info

Title:
Preliminary Analysis of the Effect of Jiangan Xiaozhi Recipe on Insulin Resistance and Lipid Deposition and Different Expressions of Related mRNA in Non-alcoholic Fatty Liver Disease
文章编号:
1000-2723(2019)02-0001-10
作者:
房 昉12温伟波1△万春平1谢雪华1祁 燕1宋 云3陶丽玲3杨云姣3
(1. 云南中医药大学第一附属医院,云南 昆明650021;2. 南京中医药大学,江苏 南京 210023;3. 云南中医药大学临床医学院,云南 昆明650500)
Author(s):
FANG Fang12 WEN Weibo1 WAN Chunping1 XIE Xuehua1 QI Yan1 SONG Yun3 TAO Liling3 YANG Yunjiao3
(1. The First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming 650021 , China;2. Nanjing University of Chinese Medicine, Nanjing 210023 , China; 3. Clinical Medical College of Yunnan University of Chinese Medicine, Kunming, 650500, China)
关键词:
健肝消脂方 非酒精性脂肪性肝病 胰岛素抵抗 脂质沉积 基因芯片
Keywords:
Jiangan Xiaozhi Recipe non-alcoholic fatty liver diseaseinsulin resistance lipid deposition gene chip
分类号:
R285.5
DOI:
10.19288/j.cnki.issn.1000-2723.2019.02.001
文献标识码:
A
摘要:
目的通过观察动物模型空腹胰岛素、空腹血糖、肝脏脂质沉积情况,计算胰岛素抵抗(IR)相关指标,并使用基因芯片技术观察相关mRNA表达谱差异,以深入阐释健肝消脂方治疗非酒精性脂肪性肝病(NAFLD)的分子机制。方法 使用高糖高脂饲料复制NAFLD大鼠模型,造模成功后使用随机数字表法分为治疗组(Z组)及模型组(M组)。Z组根据10.86g/kg的生药量予健肝消脂方灌胃给药,M组给予等体积的蒸馏水灌胃,均每日给药1次,连续60天。给药结束后检测两组空腹胰岛素水平、空腹血糖水平,计算胰岛素敏感性及胰岛素抵抗指数(HOMA-IR),肝脏病理切片染色后观察肝脏脂质沉积情况,采用基因芯片技术分析实验动物肝脏相关mRNA表达谱差异。结果 与M组比较,Z组大鼠空腹胰岛素水平明显下降(P<0.05),胰岛素敏感性明显升高(P<0.05),HOMA-IR明显降低(P<0.05),肝脏脂质沉积明显改善;两组肝脏mRNA表达存在明显差异(P<0.05),其中上调的基因有52个,下调的基因有13个;对基因功能进行分析可知,生物途径(pathway)富集可得出排序前十的pathway富集结果,GO富集可得到8个GO分子功能(molecular function)富集结果,排序前十的GO生物过程(biological process)富集结果及2个GO细胞成分(cellular component)富集结果。结论 健肝消脂方可以改善IR及肝脏脂质沉积,其作用机制可能与该方影响肝脏基因表达有关。其分子机制可能是该方能够调节干扰素调节因子(IRF)7、GO分子功能GO:0016597、GO生物过程GO:0006952,并且影响了血管内皮生长因子(VEGF)信号通路、丝裂原活化蛋白激酶(MAPK)信号通路、Toll样体信号通路。同时健肝消脂方可能在分子层面上对肝纤维化、丙型肝炎病毒在肝脏内的复制等产生一定影响。
Abstract:
Objective To further explain the molecular mechanism of Jiangan Xiaozhi Recipe in the treatment of non-alcoholic fatty liver disease (NAFLD), by investigating the fasting insulin, fasting blood glucose and liver lipid deposition in animal models and calculating insulin resistance(IR) related indicators, and observing the differences of related mRNA expression profiles by using gene chip technology. Methods NAFLD rat models were reproduced with high-sugar and high-fat diet. After successful establishment, the models were divided into treatment group (Z group) and model group (M group),according to random number table. Group Z was given Jiangan Xiaozhi Recipe orally once a day for 60 consecutive days according to the dosage of 10.86 g/kg. Group M was given distilled water of equal volume once a day for 60 consecutive days. Fasting insulin and fasting blood glucose levels were measured after intervention. Insulin sensitivity and insulin resistance index (HOMA-IR) were calculated. Liver pathological sections were stained to observe liver lipid deposition. Gene chip technology was used to analyze the different expressions of related mRNA in experimental animals' livers. Results Compared with group M, fasting insulin level of rats in group Z decreased significantly(P<0.05), insulin sensitivity increased significantly (P<0.05), HOMA-IR decreased significantly(P<0.05), and liver lipid deposition improved significantly(P<0.05). There were significant differences in liver gene expression between the two groups(P<0.05), including 52 up-regulated genes and 13 down-regulated genes. The results of pathway enrichment in the first ten rankings can be obtained. The results of molecular function enrichment can be obtained by GO enrichment. The biological process enrichment of GO in the first ten rankings and cell component enrichment of two GO cells can be obtained by GO enrichment. Conclusion Its molecular mechanism may be that Jiangan Xiaozhi Recipe can effect vascular endothelial growth factor(VEGF) signaling pathway, mitogen-activated protein kinase(MAPK) signaling pathway, and Toll-like receptor signaling pathway ,meanwhile adjusted interferon regulatory factor 7(IRF7), GO:0016597 of GO molecular function and GO:0006952 of GO biological process. At the same time, Jiangan Xiaozhi Recipe may have an effect on liver fibrosis and hepatitis C virus at the molecular level.

参考文献/References

[1] 葛均波,徐永健,王辰. 内科学[M]. 北京:人民卫生出版社,2018:391-392,766-767.
[2] 李秀钧. 代谢综合征(胰岛素抵抗)[M]. 北京:人民卫生出版社,2007:50,80-81.
[3] 张军汉,傅国琴,翟惠虹,等. 血糖正常者非乙醇性脂肪肝与高胰岛素血症的相关性[J]. 第四军医大学学报,2006,27(6):524-526.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版)[J]. 中华肝脏病杂志,2018,26(3):195-203.
[5] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志,2018,10(1):4-67.
[6] 杨坤,胡克章,黄正明,等. 高糖高脂肪饲料诱导大鼠非酒精性脂肪性肝病模型的动态研究[J]. 解放军药学学报,2010,26(6):509-512.
[7] 陈烁. 基于ROS探讨健肝消脂方调节IR改善NAFLD的机制[D]. 昆明:云南中医药大学,2019.
[8] 刘蓓. 新型查耳酮衍生物MW-9抗实验性自身免疫性脑脊髓炎的作用及机理研究[D]. 昆明:云南中医药大学,2019.
[9] 陈杰,张晶,何秋水. Toll样受体在非酒精性脂肪性肝病发生发展中的作用[J]. 临床肝胆病杂志,2015,31(7):1153-1155.
[10] KWON E Y, CHOI M S. Luteolin targets the toll-like receptor signaling pathway in prevention of hepatic and adipocyte fibrosis and insulin resistance in diet-induced obese mice[J]. Nutrients,2018,10(10):1415.
[11] DESBOIS A C, CACOUB P. Diabetes mellitus, insulin resistance and hepatitis C virus infection:A contemporary review[J]. World Journal of Gastroenterology,2017,23(9):1697-1711.
[12] GASTALDI G, GOMES D, SCHNEITER P, et al. Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients[J]. PLoS One,2019,14(6):e0217751.
[13] BONDINI S, YOUNOSSI Z M. Non-alcoholic fatty liver disease and hepatitis C infection[J]. Minerva Gastroenterol Dietol,2006,52(2):135-143.
[14] 丁汝璇. RIG-I样受体信号通路及其调控研究综述[J]. 中外医学研究,2019,17(14):184-186.
[15] 余美霞,刘迅,杜柳涛,等. 经典途径IKKα和IKKβ在胰岛素抵抗和2型糖尿病中的作用机制及药物治疗[J]. 中国新药杂志,2017,26(5):535-541.
[16] 陈丽,陈瑞,梁凤霞,等. NF-κB信号通路与胰岛素抵抗[J]. 华中科技大学学报(医学版),2015,44(5):608-611.
[17] LAFYATIS R, FARINA A. New insights into the mechanisms of innate immune receptor signalling in fibrosis[J]. Open Rheumatology Journal,2012,6(1):72-79.
[18] 王妍,林孝发,张微微,等. 重组人干扰素β-1a注射液对大鼠肝纤维化模型的治疗作用[J]. 长春中医药大学学报,2015,31(5):904-907.
[19] YEE H Y,杨晶晶,万毅刚,等. 胰岛素抵抗的分子机制及中药的干预作用[J]. 中国中药杂志,2019,44(7):1289-1294.
[20] 孙雪梅,黄秀昆,朱勋帅,等. 基于MAPK信号通路研究4-羟基苯并恶唑-2-酮抗肝纤维化的作用机制[J]. 中国医院药学杂志,2019,39(1):25-28.
[21] WANG T, TAKIKAWA Y, SATOH T, et al. Carnosic acid(CA)prevents lipid accumulation in hepatocytes through the EGFR/MAPK pathway[J]. Journal of Gastroenterology,2012,47(7):805-813.
[22] 孙洁,王一民,廖琳. VEGF-B 与 2 型糖尿病相关性研究进展 [J]. 世界最新医学信息文摘,2019,19(6):58-60.
[23] 陈兰羽,马继征,刘咏梅,等. 基于HIF-1α介导的VEGF mRNA表达探讨膈下逐瘀汤抗肝纤维化血管新生的机制[J]. 中草药,2019,50(2):449-456.
[24] 王倩,吴鹏波,李明,等. VEGF基因多态性及吸烟在诱发非酒精性脂肪肝中的交互作用[J]. 山东医药,2016,56(8):7-9.
[25] 叶小珍,邵加庆,王坚. 花生四烯酸及其代谢产物在胰岛β细胞功能及胰岛素抵抗中的作用[J]. 中国全科医学,2009,12(2):160-162.
[26] 章烁,阳学风. 花生四烯酸氧化应激与非酒精性脂肪性肝病的研究进展[J]. 中国现代医生,2013,51(34):19-22.
[27] HONDA K, YANAI H, MIZUTANI T, et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-Like receptor signaling[J]. Proceedings of the National Academy of Sciences of the United States of America,2004,101(43):15416-15421.
[28] BELL J K, MULLEN G E, LEIFER C A, et al. Leucine-rich repeats and pathogen recognition in Toll-like receptors[J]. Trends in Immunology,2003,24(10):528-533.
[29] INOUE H, HISAMOTO N, AN J H, et al. The C. elegans p38 MAPK pathway regulates nuclear localization of the transcription factor SKN-1 in oxidative stress response[J]. Genes Dev,2005,19(19):2278-2283.
[30] LIN R, LACOSTE J, NAKHAEI P, et al. Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage[J]. Journal of Virology,2006,80(12):6072-6083.
[31] 丁罡,宋明志,于尔辛. 丹参、赤芍对大鼠Walker 256癌肝转移影响机制的研究[J]. 中国癌症杂志,2001,11(4):364-366.
[32] 李琦,王炎,范忠泽,等. 丹参酮ⅡA及其纳米粒诱导肝癌细胞凋亡及对p38 MAPK、TGFβ1信号蛋白表达的影响[J]. 肿瘤,2008,28(1):8-12.
[33] 王喜福,叶明,颜东,等. 丹参多酚酸盐对急性心肌梗死PCI术后CD14+单核细胞活性氧和Toll样受体的影响[C]// 2014年中华中医药学会急诊分会年会暨急诊医学培训班论文集. 北京:中华中医药学会急诊分会,2014.
[34] 张金生,何庆勇. 三七总皂苷对不同时点心梗大鼠心肌VEGF、bFGF蛋白表达的影响[J]. 中华中医药杂志,2009,24(11):1496-1499.
[35] 李宝石,夏宁俊,朱超林. 中药莪术对肿瘤相关信号通路影响研究进展[J]. 辽宁中医药大学学报,2015,17(2):188-191.
[36] 沈洪,刘增巍,张坤,等. 黄芪对SGC7901胃癌细胞COX-1、COX-2、VEGF和PGE_2表达的影响[J]. 肿瘤,2007,27(3):194-198.
[37] 张海燕,刘忠锦,陈志伟. 赤芍总苷对D-半乳糖诱导衰老大鼠脑组织TOLL受体和IL-33的实验研究[J]. 中国中西医结合杂志,2013,33(6):830-833.
[38] 詹丽英,夏中元,夏芳,等. p38MAPK/iNOS/HO-1信号通路在赤芍减轻大鼠内毒素性急性肺损伤中的作用[J]. 中华麻醉学杂志,2009,29(3):258-261.
[39] 唐春兰,杨和平,李剑明,等. 姜黄素Ⅲ对A549裸鼠移植瘤VEGF蛋白表达的影响[J]. 第三军医大学学报,2005,27(9):831-833.
[40] 陈茜,陈丽娟,党媛媛,等. 姜黄素通过阻滞MAPK/ERK通路抑制人子宫内膜癌HEC-1-B细胞的侵袭转移[J]. 山西医科大学学报,2015,46(8):762-768.
[41] 张雪梅. 荷叶生物碱对人主动脉内皮细胞VEGF-A表达及功能的影响[D]. 东莞:广东医学院,2016.
[42] 廖二元. 内分泌代谢病学[M]. 北京:人民卫生出版社,2012:1004-1005
[43] CANSAN?覶?魨O K, SILVA M L, CARVALHO L N, et al. Advanced liver fibrosis is independently associated with palmitic acid and insulin levels in patients with non-alcoholic fatty liver disease[J]. Nutrients,2018,10(11):1586.

备注/Memo

备注/Memo:
收稿日期: 2019 - 03- 12
* 基金项目: 国家自然科学基金地区科学基金(81560772)
第一作者简介: 房昉(1982-),男,在读博士研究生,主治医师,研究方向:中医药治疗内分泌代谢病。
△通信作者: 温伟波,E-mail:dcwenweibo@sina.com
更新日期/Last Update: 2019-11-19